Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
William Blair assigns Climb Bio an Outperform rating, projecting peak sales of $1.9 billion and long-term growth for its therap...
- SEC Filing
Morgan Stanley analyst Matthew Harrison maintains Biogen (NASDAQ:BIIB) with a Equal-Weight and raises the price target from ...
– An analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed continuing improveme...
New LEQEMBI Companion™ program launched to expand helpful resources for patients throughout the treatment journey, including Nu...
Tech and AI-related stocks continued to propel Wall Street to new record highs Monday, with Advanced Micro Devices Inc. (NASDAQ...
Health care stocks rallied after Trump struck a drug pricing deal with Pfizer, offering major discounts and pausing pharma tari...
Wall Street posts modest gains as shutdown begins and jobs data disappoints, but optimism around earnings and rate cuts keeps m...
